目的 探讨氩氦刀冷冻消融序贯重组人血管内皮抑制素注射液（商品名为恩度，以下简称恩度）治疗复治的晚期非小细胞肺癌的临床疗效。

Objective To investigate the clinical efficacy of Ar-He cryoablation combined with recombinant human endostatin in treatment of advanced refractory non-small cell lung cancer. Methods Thirty stage Ⅲ and stage Ⅳ refractory non-small cell lung cancer patients were randomly divided into two groups. One group included eighteen patients who received recombinant human endostatin therapy one week after cryoablation. The other group consisted of twelve patients that received Ar-He cryoablation alone. The CT scan of the chest and survival time was followed up after the treatment. Results The clinical response rate was found to be pretty much the same one month after treatment in the two groups, but was significantly higher in the cryoablation+endorstar group than in the cryoablation group three months and six months after treatment. The median survival time was 279 days in the cryoablation + endorstar group and 258 days in the cryoablation group; the difference was significant between the two groups（P<0.01）. Conclusions Better clinical efficacy can be achieved in treating advanced refractory non-small cell lung by cryoablation combined with recombinant human endostatin.